ESMO Congress 2026

First, the source ecosystem: #CRCSM is an X hashtag community where colorectal cancer clinicians and researchers gather, and both live posts here came through this channel. A prior systematic review showed that prevention was the most common information CRC patients looked for on social media, followed by treatment side effects, that doctors made up only 2% of CRC social media users, and that engagement by colorectal surgeons was clearly suboptimal ^[3]; an analysis of early-onset colorectal and pancreatic cancer posts from 2023 to 2025 further showed that 66.1% of posts were academic and clinical content, while only 0.2% (11 posts) described patient experiences ^[6]. These live posts belong to that academic-style, first-hand conference intelligence. Notably, the background materials provided do not include previously published pivotal trial evidence for PD-1 plus CTLA-4 in MSI-H/dMMR metastatic colorectal cancer—pending confirmation.

At the 2026 ESMO Congress, CheckMate 8HW reported final overall survival (OS) for NIVO+IPI in centrally confirmed MSI-H/dMMR metastatic colorectal cancer, with median follow-up of approximately 68 months. The numbers, copied verbatim: all lines versus NIVO monotherapy, OS HR 0.61 (0.46–0.82), p=0.0009, with 5-year OS of 74% vs 62%; first-line versus NIVO monotherapy, HR 0.66 (0.44–0.99), p=0.043, which missed the prespecified boundary (p<0.0058), with 5-year OS of 77% vs 66%; first-line versus chemotherapy, OS HR 0.37, p<0.0001; safety was stable overall, with low grade 3/4 events.

In terms of what this advances, the update moves the evidence for dual checkpoint inhibition in this population to final OS at roughly 68 months of follow-up: across all lines, NIVO+IPI was superior to NIVO monotherapy (HR 0.61, p=0.0009), while the formal first-line comparison against monotherapy, although directionally favorable, did not cross the prespecified boundary (p<0.0058) and should be interpreted cautiously within the trial's testing strategy; the first-line versus chemotherapy figure of HR 0.37 is a separate parallel comparison, and the three sets of data should not be conflated. The other live post from the same meeting is a preview in nature: Dr. Sinicrope of Mayo Clinic, in an OncLive video, flagged two colorectal cancer studies to watch at the 2026 ESMO Congress—adjuvant treatment intensification and the AZUR-1 trial—with no specific numbers disclosed.

Limitations should be noted: these figures come from conference social media live posts rather than a formal abstract; beyond the verbatim HRs, p values, and 5-year OS rates, median OS, subgroup analyses, and the full testing hierarchy are undisclosed; the adjuvant intensification study and AZUR-1 are so far only at the title level, and interpretation should await the formal presentations.